168 related articles for article (PubMed ID: 31647032)
1. Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study.
Li J; Kong XX; Zhou JJ; Song YM; Huang XF; Li GH; Ying XJ; Dai XY; Lu M; Jiang K; Fu DL; Li XL; He JJ; Wang JW; Sun LF; Xu D; Xu JY; Chen M; Tian Y; Li JS; Yan M; Yuan Y; Ding KF
BMC Cancer; 2019 Oct; 19(1):988. PubMed ID: 31647032
[TBL] [Abstract][Full Text] [Related]
2. Fast track multi-discipline treatment (FTMDT trial) versus conventional treatment in colorectal cancer--the design of a prospective randomized controlled study.
Zhou JJ; Li J; Ying XJ; Song YM; Chen R; Chen G; Yan M; Ding KF
BMC Cancer; 2011 Nov; 11():494. PubMed ID: 22111914
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of safety and efficacy of enhanced recovery pathways in stage II-III colorectal cancer patients submitted to surgery and adjuvant therapy.
Wang B; Wu Z; Zhang R; Chen Y; Dong J; Qi X
World J Surg Oncol; 2021 Apr; 19(1):99. PubMed ID: 33823871
[TBL] [Abstract][Full Text] [Related]
5. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
6. Perioperative strategy in colonic surgery; LAparoscopy and/or FAst track multimodal management versus standard care (LAFA trial).
Wind J; Hofland J; Preckel B; Hollmann MW; Bossuyt PM; Gouma DJ; van Berge Henegouwen MI; Fuhring JW; Dejong CH; van Dam RM; Cuesta MA; Noordhuis A; de Jong D; van Zalingen E; Engel AF; Goei TH; de Stoppelaar IE; van Tets WF; van Wagensveld BA; Swart A; van den Elsen MJ; Gerhards MF; de Wit LT; Siepel MA; van Geloven AA; Juttmann JW; Clevers W; Bemelman WA
BMC Surg; 2006 Nov; 6():16. PubMed ID: 17134506
[TBL] [Abstract][Full Text] [Related]
7. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
Kosugi C; Koda K; Ishibashi K; Yoshimatsu K; Tanaka S; Kato R; Kato H; Oya M; Narushima K; Mori M; Shuto K; Ishida H
Int J Colorectal Dis; 2018 Jun; 33(6):809-817. PubMed ID: 29484450
[TBL] [Abstract][Full Text] [Related]
8. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Lu GC; Fang F; Li DC
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):152-5. PubMed ID: 20403249
[TBL] [Abstract][Full Text] [Related]
10. Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
Wang Z; Liang L; Yu Y; Wang Y; Zhuang R; Chen Y; Cui Y; Zhou Y; Liu T
Cell Physiol Biochem; 2016; 39(3):1239-46. PubMed ID: 27595400
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
13. Laparoscopic surgery contributes more to nutritional and immunologic recovery than fast-track care in colorectal cancer.
Xu D; Li J; Song Y; Zhou J; Sun F; Wang J; Duan Y; Hu Y; Liu Y; Wang X; Sun L; Wu L; Ding K
World J Surg Oncol; 2015 Feb; 13():18. PubMed ID: 25649903
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis.
Wu Y; Liu F; Song W; Liang F; Wang L; Xu Y
Am J Surg; 2019 Nov; 218(5):894-898. PubMed ID: 30268420
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y; Shimokawa M; Tanaka T; Emi Y; Oki E; Saeki H; Sadanaga N; Kusumoto T; Touyama T; Kimura M; Baba H; Akagi Y; Shirouzu K; Maehara Y;
Int J Clin Oncol; 2016 Apr; 21(2):335-343. PubMed ID: 26338269
[TBL] [Abstract][Full Text] [Related]
17. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
18. On 5-fluorouracil therapy of colorectal cancer.
Jensen SA
Dan Med J; 2013 Jul; 60(7):B4603. PubMed ID: 23809976
[No Abstract] [Full Text] [Related]
19. Effectiveness of fast-track rehabilitation vs conventional care in laparoscopic colorectal resection for elderly patients: a randomized trial.
Wang Q; Suo J; Jiang J; Wang C; Zhao YQ; Cao X
Colorectal Dis; 2012 Aug; 14(8):1009-13. PubMed ID: 21985126
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
